SmokingPSPNCT04282694
PRogetto Salute Parma
An observational study of Smoking and Smoking Habit, run by University of Parma at 1 site in Italy.
Trial summary
This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention… Read more about this study
- Who is it for?
- Ages 50 to 74 yearsHealthy volunteers can take part
- Conditions the study is for
- Smoking, Smoking Habit, Smoking, Tobacco
- What is being tested?
- Low-dose computed tomography (LDCT)
- How many people
- 9 participants
- Where
- 1 siteItaly
- Study dates
- 12 Feb 2020to 30 Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 74 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
Who may be able to join
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Who cannot join
- Personal history of cancer within the prior 5 years
Trial locations and contacts
1 site in 1 country.
About this study
Official title: PRogetto Salute Parma: PRevenzione Primaria e Secondaria Del Danno da Fumo
This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).
Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.
Read more
The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.
Secondary objectives:
- To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
- To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
- To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)
Primary endpoint:
- Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
Secondary endpoints:
- To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
- To measure the variation in smoking habits in enrolled smokers
- To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
- To measure the consequent demand for further diagnostic investigations and treatment
- To measure the number of false positives
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
Inclusion criteria
- Age between 50 and 75 years
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Exclusion criteria
- Personal history of cancer within the prior 5 years
We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs:
- Statistical methods planned in the study protocol;
- Size of the sample;
- Management of missing data;
- Evaluation of the endpoints;
- Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.
The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.
- Conditions
- Smoking, Smoking Habit, Smoking, Tobacco, Smoking, Cigarette, Smoking Cessation, Lung Cancer
- Being tested
- Low-dose computed tomography (LDCT)
- Medical subject headings
- Smoking, Tobacco Smoking, Cigarette Smoking, Smoking Cessation, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-dose computed tomography (LDCT)Diagnostic test
Also called Smoking cessation
Early detection of lung cancer by LDCT and smoking cessation counselling
| Study group | Role | What they receive |
|---|---|---|
| High risk (former) smokers | Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
Inclusion criteria
* Age between 50 and 75 years
* Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
* Status of current smoker or ex-smoker for <10 years.
Exclusion criteria
• Personal history of cancer within the prior 5 years Receives: Diagnostic Test: Low-dose computed tomography (LDCT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence
Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
Measured: 12 months
Secondary outcomes (5)
Organization model
To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
Measured: 18 months
Smoking cessation
To measure the variation in smoking habits in enrolled smokers.
Measured: 24 months
Secondary prevention of lung cancer
To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site.
Measured: 24 mesi
Work up burden
To measure the demand for further diagnostic investigations and treatment generated by LDCT.
Measured: 24 months
False positives
To measure the number of false positives generated by LDCT
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2020
- Study start12 Feb 2020
- Primary completion30 Oct 2020
- Study completion30 Oct 2020
Why it stopped: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SmokingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Parma
- Sponsor type
- University, hospital or other
- Collaborators
- Azienda Ospedaliero-Universitaria di Parma, Azienda Unità Sanitaria Locale di Parma
- Responsible party
- Sponsor
- Investigators
- Nicola Sverzellati, MD, PhD, Principal investigator, University of Parma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04282694
- Sponsor's protocol ID
- 837/2019/OSS/UNIPR
- Acronym
- PSP
- Status last verified
- Feb 2020
- First submitted
- 20 Feb 2020
- Last updated
- 19 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRogetto Salute Parma: PRevenzione Primaria e Secondaria Del Danno da Fumo
- ClinicalTrials.gov ID
- NCT04282694
- Acronym / sponsor ID
- PSP / 837/2019/OSS/UNIPR
- Conditions
- Smoking, Smoking Habit, Smoking, Tobacco, Smoking, Cigarette, Smoking Cessation, Lung Cancer
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.
- Enrolment
- 9 participants (actual)
- Lead sponsor
- University of ParmaUniversity, hospital or other
- Collaborators
- Azienda Ospedaliero-Universitaria di Parma, Azienda Unità Sanitaria Locale di Parma
- Study start
- 12 Feb 2020 (actual)
- Primary completion
- 30 Oct 2020 (actual)
- Study completion
- 30 Oct 2020 (actual)
- First posted
- 25 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).
Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.
The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.
Secondary objectives:
- To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
- To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
- To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)
Primary endpoint:
- Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
Secondary endpoints:
- To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
- To measure the variation in smoking habits in enrolled smokers
- To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
- To measure the consequent demand for further diagnostic investigations and treatment
- To measure the number of false positives
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
Inclusion criteria
- Age between 50 and 75 years
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Exclusion criteria
- Personal history of cancer within the prior 5 years
We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs:
- Statistical methods planned in the study protocol;
- Size of the sample;
- Management of missing data;
- Evaluation of the endpoints;
- Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.
The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| High risk (former) smokers | – | Diagnostic Test: Low-dose computed tomography (LDCT)Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria * Age between 50 and 75 years * Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years * Status of current smoker or ex-smoker for <10 years. Exclusion criteria • Personal history of cancer within the prior 5 years |
Who may qualify
- Ages
- 50 to 74 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
Key inclusion criteria (2 listed)
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Key exclusion criteria (1 listed)
- Personal history of cancer within the prior 5 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-dose computed tomography (LDCT)Also: Smoking cessationEarly detection of lung cancer by LDCT and smoking cessation counselling | Diagnostic test | High risk (former) smokers |
Primary outcome
Adherence
Time frame: 12 months
Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
5 secondary outcomes
Organization model
Time frame: 18 months
Smoking cessation
Time frame: 24 months
Secondary prevention of lung cancer
Time frame: 24 mesi
Work up burden
Time frame: 24 months
False positives
Time frame: 24 months
Results and safety
The study was stopped early (reason given: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2021.
Related trials for Smoking
Not yet recruiting
The Effects of Manual Acupuncture on Superoxide Dismutase Enzyme Activity and Questionnaire of Smoking Urges-Brief Scores in Active Smokers: A Randomized Controlled Trial
Superoxide Dismutase, Acupuncture
Recruiting
Smoking Cessation in Patients With Cancer
Cancer, Tobacco Use
RecruitingPhase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
Alcohol Drinking
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruiting
Effectiveness Of Project EX: A Classroom-Based Smoking Prevention And Cessation Intervention Program
Focus of the Study is Smoking Cessation and Prevention, Smoking Prevention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicola Sverzellati, MD, PhD principal investigator
University of Parma
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Smoking and Smoking Habit, run by University of Parma at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 19 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adherence (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2021.